Thomas Clozel talks quickly. Very quickly. At times his thoughts seem to be generated faster than conversational language can organise them, with a new idea arriving before the previous one has been serialised.
It's a fitting trait for a man who, as CEO and co-founder of the AI biology company Owkin, has spent years trying…
Longevity has stopped being a Silicon Valley curiosity. Over the past four years, the field has crossed the line from speculative science to institutional industry. Tech billionaires have poured billions into it. Sovereign wealth funds have arrived. The first human trial of partial cellular reprogramming starts this year, with FDA clearance already in hand. A…



